Perspective Therapeutics updates corporate presentation; no material new data disclosed

Perspective Therapeutics, Inc.

Updated corporate presentation filed August 1, 2025; no new clinical data or financial guidance disclosed.
Pipeline includes [212Pb]VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 targeting FAP-α.
Presentation notes sustained anti-tumor activity and tolerability for NET trial; no quantitative updates.
Pre-targeting platform and supply chain infrastructure highlighted as key differentiators.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.